文献速递神经肿瘤功能神经外科

脑转移瘤切除术患者术前与术后癫痫发作的相关因素

Factors associated with preoperative and postoperative seizures in patients undergoing resection of brain metastases.
PubMed 文献 · J Neurosurg · 2022-04-29

该研究回顾性分析了1998至2019年在加州大学旧金山分校接受脑转移瘤切除术的348例连续患者,平均年龄60岁,女性占59%。术前癫痫发作见于近四分之一患者,额叶转移和瘤内出血是术前发作的独立预测因素,而检查点抑制剂使用和顶叶肿瘤与术后6个月癫痫发作显著相关。

要点

  • 术前癫痫发作见于近四分之一脑转移瘤手术患者。
  • 额叶转移和瘤内出血是术前癫痫发作的独立预测因素。
  • 检查点抑制剂使用和顶叶肿瘤与术后6个月癫痫发作显著相关。

核心结论

  • 在该脑转移瘤手术队列中,术前癫痫发作见于近四分之一患者;额叶转移和出血性肿瘤与术前癫痫发作风险较高相关,而检查点抑制剂使用和顶叶肿瘤似乎与术后6个月癫痫发作相关。
  • 未来研究应关注针对转移病灶的治疗干预对这类患者癫痫控制的影响。

研究设计与样本

  • 回顾性分析1998至2019年在加州大学旧金山分校接受脑转移瘤切除术的348例连续患者,纳入标准为年龄≥18岁且需行脑转移瘤切除术。
  • 原发癌包括黑色素瘤、非小细胞肺癌腺癌、乳腺腺癌、结直肠腺癌、食管腺癌、胃腺癌、肾细胞癌、尿路上皮癌、卵巢癌、宫颈鳞状细胞癌和子宫内膜腺癌。
  • 评估原发癌类型与癫痫发作情况,以及术前、出院时和术后6个月抗癫痫药物使用需求;对术前有癫痫发作的患者进行Engel分类评分。
  • 采用单变量和多变量回归分析评估肿瘤类型与术前癫痫发作的关联。

主要发现

  • 队列平均手术年龄为60岁,女性占59%;术后平均随访22个月,中位随访10.8个月。
  • 单变量分析中,额叶位置(p=0.05)、黑色素瘤(p=0.02)、肺癌KRAS突变(p=0.04)、瘤内出血(p=0.04)和既往放疗(p=0.04)与癫痫发作表现相关。
  • 术后6个月癫痫发作相关的因素包括检查点抑制剂使用(p=0.002)、既往放疗(p=0.05)、年龄较大(p=0.002)、中枢神经系统远处进展(p=0.004)和顶叶肿瘤位置(p=0.002)。
  • 最终多变量模型证实额叶肿瘤位置和瘤内出血是术前癫痫发作的独立预测因素,检查点抑制剂使用和顶叶位置是术后6个月癫痫发作的显著预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Epileptic seizures are a common and potentially devastating complication of metastatic brain tumors. Although tumor-related seizures have been described in previous case series, most studies have focused on primary brain tumors and have not differentiated between different types of cerebral metastases. The authors analyzed a large surgical cohort of patients with brain metastases to examine risk factors associated with preoperative and postoperative seizures and to better understand the seizure risk factors of metastatic brain tumors. METHODS: Patients who underwent resection of a brain metastasis at the University of California, San Francisco (UCSF), were retrospectively reviewed. Patients included in the study were ≥ 18 years of age, required resection of a brain metastasis, and were treated at UCSF. Primary cancers included melanoma, non-small cell lung adenocarcinoma, breast adenocarcinoma, colorectal adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, renal cell carcinoma, urothelial carcinoma, ovarian carcinoma, cervical squamous cell carcinoma, and endometrial adenocarcinoma. Patients were evaluated for primary cancer type and seizure occurrence, as well as need for use of antiepileptic drugs preoperatively, at time of discharge, and at 6 months postoperatively. Additionally, Engel classification scores were assigned to those patients who initially presented with seizures preoperatively. Univariate and multivariate regression analyses were used to assess the association of tumor type with preoperative seizures. RESULTS: Data were retrospectively analyzed for 348 consecutive patients who underwent surgical treatment of brain metastases between 1998 and 2019. The cohort had a mean age of 60 years at the time of surgery and was 59% female. The mean and median follow-up durations after the date of surgery for the cohort were 22 months and 10.8 months, respectively. In univariate analysis, frontal lobe location (p = 0.05), melanoma (p = 0.02), KRAS mutation in lung carcinoma (p = 0.04), intratumoral hemorrhage (p = 0.04), and prior radiotherapy (p = 0.04) were associated with seizure presentation. Postoperative checkpoint inhibitor use (p = 0.002), prior radiotherapy (p = 0.05), older age (p = 0.002), distant CNS progression (p = 0.004), and parietal lobe tumor location (p = 0.002) were associated with seizures at 6 months postoperatively. The final multivariate model confirmed the independent effects of tumor location in the frontal lobe and presence of intratumoral hemorrhage as predictors of preoperative seizures, and checkpoint inhibitor use and parietal lobe location were identified as significant predictors of seizures at 6 months postoperatively. CONCLUSIONS: Within this surgical cohort of patients with brain metastases, seizures were seen in almost a quarter of patients preoperatively. Frontal lobe metastases and hemorrhagic tumors were associated with higher risk of preoperative seizures, whereas checkpoint inhibitor use and parietal lobe tumors appeared to be associated with seizures at 6 months postoperatively. Future research should focus on the effect of metastatic lesion-targeting therapeutic interventions on seizure control in these patients.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Garcia JH, Morshed RA, Chung J, et al. Factors associated with preoperative and postoperative seizures in patients undergoing resection of brain metastases. J Neurosurg. 2022. PMID: 35535842. doi:10.3171/2022.3.JNS212285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。